BioCorRx’s Subsidiary, BioCorRx Pharmaceuticals, to Exhibit at ASAM 50th Annual Conference in Orlando, Florida
28 mars 2019 08h00 HE
|
BioCorRx Inc
ANAHEIM, CA, March 28, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (the “Company), a developer and provider of advanced solutions in the treatment of substance abuse...
BioCorRx Promotes Dr. Balbir S. Brar to Senior VP of Drug Development; Extends Service Agreement
27 mars 2019 07h37 HE
|
BioCorRx Inc
ANAHEIM, CA, March 27, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (OTC: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of substance abuse...
BioCorRx to Present at the 31st Annual ROTH Conference on March 17-19, 2019
14 mars 2019 08h00 HE
|
BioCorRx Inc
ANAHEIM, CA, March 14, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (“Company”), a developer and provider of advanced solutions in the treatment of substance use...
BioCorRx Partners with IRISYS for Manufacturing of BICX102 Naltrexone Implant for Treatment of Opioid Use Disorder
26 févr. 2019 08h00 HE
|
BioCorRx Inc
ANAHEIM, CA, Feb. 26, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (“Company”), a developer and provider of advanced solutions in the treatment of substance use...
BioCorRx Appoints Two Finance Veterans to the Board of Directors
25 févr. 2019 08h00 HE
|
BioCorRx Inc
ANAHEIM, CA, Feb. 25, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – BioCorRx Inc. (OTCQB: BICX) (“Company”), a developer and provider of advanced solutions in the treatment of substance use disorders,...
BioCorRx Announces Formation of Scientific Advisory Board
19 févr. 2019 10h26 HE
|
BioCorRx Inc
ANAHEIM, CA, Feb. 19, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use...
BioCorRx Announces Reverse Stock Split in Preparation for Proposed Uplisting to NASDAQ Capital Market
23 janv. 2019 08h00 HE
|
BioCorRx Inc
ANAHEIM, CA, Jan. 23, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX; BICXD) (the “Company”), a developer and provider of advanced solutions in the treatment of substance...
BioCorRx Awarded NIDA Grant of Approximately $5.7 Million for BICX102, a Sustained Release Naltrexone Implant for the Treatment of Opioid Use Disorder
22 janv. 2019 07h30 HE
|
BioCorRx Inc
ANAHEIM, CA, Jan. 22, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use...
BioCorRx Strengthens Intellectual Property Portfolio with Acquisition of Several Patent/Patent Pending Families
19 oct. 2018 07h30 HE
|
BioCorRx Inc
Issued patents, in addition to other intellectual property (IP) rights, cover hydrophobic drug-delivery material for BICX101 Divisional patent applications filed to strengthen BioCorRx’s ...
BioCorRx, Inc. Announces Preliminary Agreement with VDM Biochemicals to Develop and Commercialize Patented Opioid Antagonist VDM-001
09 oct. 2018 08h00 HE
|
BioCorRx Inc
ANAHEIM, CA, Oct. 09, 2018 (GLOBE NEWSWIRE) -- VDM-001 represents potential alternative to naloxone for overdose reversal; Potential to reduce cravings from substance use disorder via...